SCHEMBL4363756

SCHEMBL4363756

CC(C)CCCCCCCCCCCP

nearest known ligand 0.50

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.50
▸ TRPV1 Q8NER1 1/20 0.38
▸ TRPA1 O75762 1/20 0.38
▸ KDM4C Q9H3R0 2/20 0.32
▸ KDM4A O75164 1/20 0.32
▸ PHF8 Q9UPP1 1/20 0.32
▸ KDM2A Q9Y2K7 1/20 0.32
▸ SPHK1 Q9NYA1 1/20 0.32
▸ BLM P54132 1/20 0.31
▸ HIF1A Q16665 1/20 0.31
▸ EPAS1 Q99814 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8652515 1.00 LMNA (0.50) LMNATRPV1TRPA1KDM4CKDM4A
SCHEMBL13075202 1.00 LMNA (0.50) LMNATRPV1TRPA1KDM4CKDM4A
SCHEMBL6280786 1.00 LMNA (0.50) LMNATRPV1TRPA1KDM4CKDM4A
SCHEMBL9794655 1.00 LMNA (0.50) LMNATRPV1TRPA1KDM4CKDM4A
SCHEMBL5717469 1.00 — —
Bromide SCHEMBL5343457 0.97 LMNA (0.48) LMNATRPV1TRPA1KDM4CKDM4A
Hydrochloric Acid SCHEMBL5345632 0.97 LMNA (0.48) LMNATRPV1TRPA1KDM4CKDM4A
SCHEMBL4814282 0.97 — —
SCHEMBL2097116 0.87 — —
SCHEMBL14840292 0.85 HIF1A (0.41) LMNATRPV1TRPA1HIF1AEPAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3753059-A1 DIATOMACEOUS ENERGY STORAGE DEVICES Printed Energy Pty Ltd (AU) 2020-12-23 — — EP claimed
JP-6122855-A — — None — — JP disclosed
EP-3753059-A1 DIATOMACEOUS ENERGY STORAGE DEVICES Printed Energy Pty Ltd (AU) 2020-12-23 — — EP disclosed
US-10799610-B2 Cement products and methods of making and using the same PIONEER SURGICAL TECHNOLOGY, INC. (US) 2020-10-13 — — US disclosed
US-10413632-B2 Cement products and methods of making and using the same PIONEER SURGICAL TECHNOLOGY, INC. (US) 2019-09-17 — — US disclosed
US-20180264165-A1 CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME MIDCAP FINANCIAL TRUST 2018-09-20 — — US disclosed
US-9993576-B2 Cement products and methods of making and using the same PIONEER SURGICAL TECHNOLOGY, INC. (US) 2018-06-12 — — US disclosed
EP-2192886-B1 CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME PIONEER SURGICAL TECH INC (US) 2017-12-20 — — EP disclosed
US-20170333594-A1 CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME MIDCAP FINANCIAL TRUST 2017-11-23 — — US disclosed
US-9757493-B2 Cement products and methods of making and using the same PIONEER SURGICAL TECHNOLOGY, INC. (US) 2017-09-12 — — US disclosed
US-20160250376-A1 CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME TUTOGEN MEDICAL, INC. 2016-09-01 — — US disclosed
US-9358319-B2 Cement products and methods of making and using the same PIONEER SURGICAL TECHNOLOGY, INC. (US) 2016-06-07 — — US disclosed
US-20140357754-A1 CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME MIDCAP FINANCIAL TRUST 2014-12-04 — — US disclosed
US-8815973-B2 Cement products and methods of making and using the same PIONEER SURGICAL TECHNOLOGY, INC. (US) 2014-08-26 — — US disclosed
US-20090270527-A1 CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME ANGSTROM MEDICA (US) 2009-10-29 — — US disclosed
JP-H06122855-A PRIMER FOR CYANOACRYLATE ADHESIVE CHIKATSUNE KEIZO 1994-05-06 — — JP disclosed
US-4332733-A CATALYTIC ISOMERIZATION OF DIELS-ALDER MALEIC ANHYDRIDE PRODUCTS MITSUBISHI PETROCHEMICAL CO., LTD. (JP) 1982-06-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180264165-A1 CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME BHMT2, SHMT1, BHMT LMNA 4535/4885TRPV1 4620/4885TRPA1 3850/4885
US-20160250376-A1 CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME BHMT2, SHMT1, BHMT LMNA 4535/4885TRPV1 4620/4885TRPA1 3850/4885
US-20170333594-A1 CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME BHMT2, SHMT1, BHMT LMNA 4535/4885TRPV1 4620/4885TRPA1 3850/4885
US-10799610-B2 Cement products and methods of making and using the same BHMT2, SHMT1, BHMT LMNA 4535/4885TRPV1 4620/4885TRPA1 3850/4885
US-10413632-B2 Cement products and methods of making and using the same BHMT2, SHMT1, BHMT LMNA 4535/4885TRPV1 4620/4885TRPA1 3850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback